ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers.

Transl Psychiatry · 2025 · PMC12394601 · PMID 40877251

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

marginally significantp = .06so close (0.05 < p ≤ 0.1)

Differences between treatment and placebo were marginally significant (p = .06), and N1 amplitude was correlated with serum levels of drug suggesting some reduction in abnormally elevated N1 amplitude with BPN14770 [ 11 , 16 ].

also in 26,082 other papers

marginal significanceno p-value reported

However, individual physiological measures from electroencephalography (EEG) demonstrated only marginal significance for trial efficacy.

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.